Delivery Order SPE2DB24D2205-SPE2DB25FEBMT
- Not listed
- The Defense Logistics Agency awarded a $34,342.56 delivery order to AmerisourceBergen Drug Corp on July 16, 2025, for the supply of Takhzyro 300 mg/2 ml syringes. The contract employs firm fixed pricing with no set-aside designation, indicating competitive award through open competition. Performance is scheduled for completion by August 6, 2025, and will be executed from the contractor's corporate office location in Conshohocken, Pennsylvania. This delivery order is a child contract under...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 22, 2025, for the supply of Takhzyro 300 mg/2 ml syringes with a ceiling value of $34,342.56. This firm fixed-price delivery order is scheduled for completion by September 15, 2025, and will be fulfilled from the vendor's facility in Conshohocken, Pennsylvania. The contract was awarded on a competitive basis with no set-aside designation. This delivery order operates under AmerisourceBergen Drug Corp's...
- The Defense Logistics Agency awarded a delivery order valued at $34,342.56 to AmerisourceBergen Drug Corp for the supply of Takhzyro 300 mg/2 mL syringes on September 15, 2025. This firm fixed-price, competitively awarded contract represents a non-set-aside procurement and is scheduled for completion by October 6, 2025. AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, will perform this delivery order from its corporate office location...
- This is a federal contract award by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract, valued at $34,342.56, is for the delivery of TAKHZYRO 300 MG/2 ML SYRINGE 2ML, a specialty medication. The contract is a Firm Fixed Price Delivery Order with an ultimate completion date of April 18, 2025. AmerisourceBergen holds a significant $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop...
- This federal contract award was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor, for the supply of TAKHZYRO 300 MG/2 ML SYRINGE 2ML. The contract is a delivery order with a firm fixed price of $48,673.20 and an ultimate completion date of August 29, 2024. AmerisourceBergen holds a larger Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical valued at up to $999,999,999 through December 2025 for delivering a...
- This federal contract award, valued at $32,448.80, was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the delivery of TAKHZYRO 300 MG/2 ML SYRINGE 2ML, a specialty medication, with a completion date of April 30, 2024. This award is a delivery order under a larger Indefinite Delivery Contract (IDC) held by AmerisourceBergen with the DLA, valued at $999,999,999 and running...
- This federal contract award was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $34,342.56 firm fixed price delivery order is for TAKHZYRO 300 MG/2 ML SYRINGE 2ML, a specialty pharmaceutical product. The contract has an ultimate completion date of March 24, 2025. AmerisourceBergen holds a significant $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, which...
- This federal contract award, with a ceiling value of $32,448.80, was granted by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp's Corporate Office Division. The contract is for the delivery of TAKHZYRO 300 MG/2 ML SYRINGE 2ML, a specialty pharmaceutical product, with a completion date of May 10, 2024. Amerisourcebergen, a major pharmaceutical distribution company, holds a significant Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, valued up to...
- This federal contract award, valued at $32,448.80, was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp's Corporate Office Division. The contract is for the delivery of TAKHZYRO 300 MG/2 ML SYRINGE 2ML, a pharmaceutical product, with a completion date of July 9, 2024. Amerisourcebergen Drug Corp is a major supplier of pharmaceutical products and medical supplies to the U.S. federal government, particularly the Department of Defense (DoD) and Department of Veterans...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 8, 2025, for the supply of Taltz 80 mg/ml auto-injector medication, with a ceiling value of $1,660.30. This firm fixed-price delivery order, which is scheduled for completion by August 11, 2025, represents a continuation of AmerisourceBergen's role as a critical pharmaceutical supplier to federal medical procurement. The award was made without a set-aside designation, indicating competitive award...
- SPE2DB24D2205Indefinite Delivery Contract
- SPE2DB24D2205-SPE2DB25FEBMTDelivery Order
The Defense Logistics Agency awarded a $34,342.56 firm fixed-price delivery order to AmerisourceBergen Drug Corp for Takhzyro 300 mg/2 ml syringes on April 25, 2025, with completion required by May 16, 2025. This delivery order represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, valued at $999,999,999.00 and extending through December 2026. The award was competitively granted with no set-aside designation, and performance will occur at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. Takhzyro (iptacopan) is a first-in-class inhibitor indicated for rare complement-mediated diseases, including C3 glomerulonephritis and post-infectious glomerulonephritis. Through its prime indefinite delivery vehicle with DLA Troop Support, AmerisourceBergen supplies a comprehensive range of pharmaceutical products and medical commodities to support military healthcare systems and the Defense Health Agency. This particular delivery order fulfills specialized medication requirements within the broader pharmaceutical support mission, leveraging the company's established capabilities as a major federal pharmaceutical distributor serving defense and veteran healthcare needs.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $34.3k | 4/25/25 |